Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The drug was launched in the U.S. back in 2023 to treat obesity.
The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...
( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).